PolyPid Ltd. (NASDAQ:PYPD) Shares Acquired by Rosalind Advisors Inc.

Rosalind Advisors Inc. raised its stake in PolyPid Ltd. (NASDAQ:PYPD) by 49.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,018,021 shares of the company’s stock after acquiring an additional 338,853 shares during the period. PolyPid accounts for about 1.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 19th biggest holding. Rosalind Advisors Inc. owned about 0.10% of PolyPid worth $3,095,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Stonepine Capital Management LLC bought a new position in shares of PolyPid in the third quarter valued at $476,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on PYPD shares. HC Wainwright decreased their target price on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, December 26th. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on shares of PolyPid in a research report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 target price on the stock.

PolyPid Stock Performance

Shares of PYPD stock opened at $2.81 on Friday. The stock’s fifty day simple moving average is $3.00 and its 200-day simple moving average is $3.21. The company has a market capitalization of $28.64 million, a price-to-earnings ratio of -0.57 and a beta of 1.27. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.08. PolyPid Ltd. has a 1-year low of $2.37 and a 1-year high of $5.50.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). On average, sell-side analysts predict that PolyPid Ltd. will post -1.79 earnings per share for the current fiscal year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.